for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Cerus Corporation

CERS.OQ

Latest Trade

6.58USD

Change

0.56(+9.30%)

Volume

471,851

Today's Range

6.12

 - 

6.58

52 Week Range

2.71

 - 

7.90

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
6.02
Open
6.12
Volume
471,851
3M AVG Volume
30.04
Today's High
6.58
Today's Low
6.12
52 Week High
7.90
52 Week Low
2.71
Shares Out (MIL)
167.14
Market Cap (MIL)
1,006.20
Forward P/E
-16.27
Dividend (Yield %)
--

Next Event

Cerus Corp Annual Shareholders Meeting

Latest Developments

More

Cerus Corporation Announces Record Third Quarter 2020 Results

Cerus Q2 Revenue $26.8 Million Versus Refinitiv Ibes Estimate Of $25.9 Million

Cerus Corporation Announces FDA Pma Supplement Submission For Pathogen-Reduced Cryoprecipitated Fibrinogen Complex

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Cerus Corporation

Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company's INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The Company's INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens, such as viruses, including human immunodeficiency virus (HIV), West Nile, Severe acute respiratory syndrome (SARS), hepatitis B and C; bacteria and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma and red blood cell transfusion products. The Company's INTERCEPT Blood System is for use with blood components, including plasma, platelets, and red blood cells.

Industry

Biotechnology & Drugs

Contact Info

1220 Concord Ave Ste 600

CONCORD, CA

94520-4906

United States

+1.925.2886000

http://www.cerus.com/

Executive Leadership

Daniel N. Swisher

Independent Chairman of the Board

William M. Greenman

President, Chief Executive Officer, Director

Kevin Dennis Green

Chief Financial Officer, Vice President - Finance

Vivek K. Jayaraman

Chief Operating Officer, Chief Commercial Officer

Carol M. Moore

Senior Vice President - Regulatory Affairs, Quality and Clinical

Key Stats

1.40 mean rating - 5 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.1K

2018

0.1K

2019

0.1K

2020(E)

0.1K
EPS (USD)

2017

-0.560

2018

-0.440

2019

-0.510

2020(E)

-0.370
Price To Earnings (TTM)
--
Price To Sales (TTM)
9.39
Price To Book (MRQ)
9.21
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
40.76
LT Debt To Equity (MRQ)
36.20
Return on Investment (TTM)
-43.63
Return on Equity (TTM)
-33.03

Latest News

Latest News

BRIEF-Cerus Corp Reports Successful Inactivation Of Sars-Cov-2 With The Intercept Blood System For Plasma

* CERUS CORPORATION REPORTS SUCCESSFUL INACTIVATION OF SARS-COV-2 WITH THE INTERCEPT BLOOD SYSTEM FOR PLASMA

BRIEF-Cerus Corp Says Adopted Cerus Corp Executive Nonqualified Excess Plan

* CERUS CORP - ON MAY 21, ADOPTED CERUS CORPORATION EXECUTIVE NONQUALIFIED EXCESS PLAN

BRIEF-Cerus Corporation Announces FDA Pma Supplement Submission For Pathogen-Reduced Cryoprecipitated Fibrinogen Complex

* CERUS CORPORATION ANNOUNCES FDA PMA SUPPLEMENT SUBMISSION FOR PATHOGEN-REDUCED CRYOPRECIPITATED FIBRINOGEN COMPLEX

BRIEF-Cerus Corporation Announces First Quarter 2020 Results

* Q1 REVENUE $24.6 MILLION VERSUS REFINITIV IBES ESTIMATE OF $23.1 MILLION

BRIEF-Cerus Corporation Announces FDA Approval For Intercept Blood System

* CERUS CORPORATION ANNOUNCES FDA APPROVAL FOR INTERCEPT BLOOD SYSTEM FOR PLASMA WITH ALTERNATE PLASTIC DISPOSABLE KITS Source text for Eikon: Further company coverage:

ADVISORY-Alert wrongly coded to Cerus Corp withdrawn

The alert from an advisory firm Cerus Advisors DMCC acquiring Laboratori Derivati Organici SpA is wrongly coded to Cerus Corp , a biomedical products company, and has been withdrawn. There will be no substitute.

BRIEF-Cerus Announces Expansion Of BARDA Funding To Support Development Of Intercept Blood System For RBCs

* CERUS CORPORATION ANNOUNCES EXPANSION OF BARDA FUNDING TO SUPPORT DEVELOPMENT OF INTERCEPT BLOOD SYSTEM FOR RED BLOOD CELLS

BRIEF-Cerus Corporation Provides Update On Covid-19 Related Activities

* CERUS CORPORATION PROVIDES UPDATE ON COVID-19 RELATED ACTIVITIES

BRIEF-Cerus Corporation Announces The Inclusion Of Pathogen Reduction Technology In The ISBT Working Party Recommendations For The Preparation Of COVID-19 Convalescent Plasma

* CERUS CORPORATION ANNOUNCES THE INCLUSION OF PATHOGEN REDUCTION TECHNOLOGY IN THE ISBT WORKING PARTY RECOMMENDATIONS FOR THE PREPARATION OF COVID-19 CONVALESCENT PLASMA Source text for Eikon: Further company coverage:

BRIEF-Cerus Posts Quarterly Loss Per Share Of $0.12

* ORATION ANNOUNCES RECORD FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS

BRIEF-U.S. Department Of Defense Awards Funding For Study To Evaluate The Use Of Intercept Plasma In Traumatic Burn Resuscitation

* U.S. DEPARTMENT OF DEFENSE AWARDS FUNDING FOR STUDY TO EVALUATE THE USE OF INTERCEPT PLASMA IN TRAUMATIC BURN RESUSCITATION

BRIEF-Cerus Corp Reports Q1 Loss Per Share $0.11

* Q1 EARNINGS PER SHARE VIEW $-0.12 -- THOMSON REUTERS I/B/E/S

BRIEF-Cerus Announces Health Canada Approval Of The Intercept Blood System For Platelets

* CERUS ANNOUNCES HEALTH CANADA APPROVAL OF THE INTERCEPT BLOOD SYSTEM FOR PLATELETS Source text for Eikon: Further company coverage:

BRIEF-Cerus’ Redes Phase 3 Red Blood Cell Study Expands Into The Continental U.S.

* ’ REDES PHASE 3 RED BLOOD CELL STUDY EXPANDS INTO THE CONTINENTAL U.S.

BRIEF-Cerus Announces The Fourth Biologics License Application Approval For A U.S. Blood Center Customer

* CERUS ANNOUNCES THE FOURTH BIOLOGICS LICENSE APPLICATION (BLA) APPROVAL FOR A U.S. BLOOD CENTER CUSTOMER

BRIEF-Cerus Corp Reports Q4 Loss Per Share $0.10

* ORATION REPORTS RECORD FOURTH QUARTER AND YEAR END 2017 RESULTS

BRIEF-Cerus Announces Pricing Of Public Offering Of Common Stock

* CERUS CORP - PRICING OF PUBLIC OFFERING OF ITS COMMON STOCK FOR PROCEEDS OF $50.0 MILLION, BEFORE DEDUCTING ESTIMATED OFFERING EXPENSES PAYABLE BY CERUS Source text for Eikon: Further company coverage:

BRIEF-Cerus Announces Public Offering Of Common Stock

* CERUS CORP - COMMENCED A REGISTERED UNDERWRITTEN PUBLIC OFFERING OF $50.0 MILLION OF ITS COMMON STOCK Source text for Eikon: Further company coverage:

BRIEF-Cerus - Chronic Anemia Phase 3 Study Met Primary Efficacy And Safety Endpoints

* CERUS REPORTS POSITIVE TOP-LINE RESULTS FROM CHRONIC ANEMIA PHASE 3 STUDY EVALUATING INTERCEPT RED BLOOD CELLS IN THALASSEMIA PATIENTS

BRIEF-Cerus Corp Expects Full Year 2017 Product Revenue To Be $43.6 Million

* CERUS CORP - CERUS' UNAUDITED PRELIMINARY PRODUCT REVENUE FOR Q4 OF 2017 WAS $16.2 MILLION

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up